FORTEO + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bone Loss
Conditions
Bone Loss, Periodontitis
Trial Timeline
Aug 1, 2004 → Jul 1, 2009
NCT ID
NCT00277706About FORTEO + Placebo
FORTEO + Placebo is a phase 1 stage product being developed by Eli Lilly for Bone Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT00277706. Target conditions include Bone Loss, Periodontitis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00277706 | Phase 1 | Completed |
Competing Products
20 competing products in Bone Loss
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Denosumab + Zoledronic Acid | Daiichi Sankyo | Phase 3 | 77 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus | Astellas Pharma | Phase 2 | 52 |
| Merestinib | Eli Lilly | Phase 1 | 33 |
| Arzoxifene + Placebo | Eli Lilly | Phase 3 | 77 |
| Tanezumab | Eli Lilly | Phase 3 | 77 |
| Anastrozole + Tamoxifen | AstraZeneca | Phase 3 | 77 |
| zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements | Novartis | Phase 3 | 77 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Zoledronic acid + Letrozole | Novartis | Phase 3 | 77 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Nilotinib | Novartis | Phase 1 | 33 |
| Reclast (ZOL446, zoledronic acid) | Novartis | Approved | 85 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid | Novartis | Phase 3 | 77 |
| zoledronic acid | Novartis | Phase 1 | 33 |
| Ruxolitinib continuous therapy | Novartis | Phase 2 | 52 |
| zoledronic acid | Novartis | Approved | 85 |